Evidence map›Paper›PMID 33083460›Full record

ArticleBioMed research international2020

1'H-Indole-3'-Carbonyl-Thiazole-4-Carboxylic Acid Methyl Ester Blocked Human Glioma Cell Invasion via Aryl Hydrocarbon Receptor's Regulation of Cytoskeletal Contraction.

Lijiao Zhao, Qiuting Shu, Hui Sun, Yunlong Ma, Dandan Kang, Yating Zhao, Jing Lu, Pei Gong, Fan Yang, Fang Wan

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Amoebicidal effect of synthetic indoles againstAntimicrobial agents and chemotherapy · 2024
    Article
  3. Review
  4. Article
  5. Targeting AhR as a Novel Therapeutic Modality against Inflammatory Diseases.International journal of molecular sciences · 2021
    Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Lijiao ZhaoDepartment of Pharmaceutical Engineering, Inner Mongolia Agricultural University, Hohhot 010018, China.
Qiuting ShuDepartment of Pharmaceutical Engineering, Inner Mongolia Agricultural University, Hohhot 010018, China.
Hui SunDepartment of Pharmaceutical Engineering, Inner Mongolia Agricultural University, Hohhot 010018, China.
Yunlong MaDepartment of Pharmaceutical Engineering, Inner Mongolia Agricultural University, Hohhot 010018, China.
Dandan KangDepartment of Pharmaceutical Engineering, Inner Mongolia Agricultural University, Hohhot 010018, China.
Yating ZhaoDepartment of Pharmaceutical Engineering, Inner Mongolia Agricultural University, Hohhot 010018, China.
Jing LuDepartment of Pharmaceutical Engineering, Inner Mongolia Agricultural University, Hohhot 010018, China.
Pei GongDepartment of Pharmaceutical Engineering, Inner Mongolia Agricultural University, Hohhot 010018, China.
Fan YangDepartment of Pharmaceutical Engineering, Inner Mongolia Agricultural University, Hohhot 010018, China.
Fang WanDepartment of Pharmaceutical Engineering, Inner Mongolia Agricultural University, Hohhot 010018, China.ORCID https://orcid.org/0000-0001-5097-9227
Inner Mongolia Agricultural University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blocking glioma cell invasion has been challenging due to cancer cells that can swiftly switch their migration mode, and agents that can block more than one migration mode are sought after. We found that small molecule 2-(1H-indole-3-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE), an endogenous aryl hydrocarbon receptor (AHR) agonist, can block more than one mode of glioma cell migration, based on cultured cell behavior captured by videos. Data from wound-healing assays and mouse xenograft glioma models corroborated ITE's migration-inhibiting effects while knocking down AHR by siRNA abolished these effects. To identify genes that mediated ITE-AHR's effect, we first collected gene expression changes upon ITE treatment by RNA-seq, then compared them against literature reported migration-related genes in glioma and that were potentially regulated by AHR. MYH9, a component of nonmuscle myosin IIA (NMIIA), was confirmed to be reduced by ITE treatment. When MYH9 was overexpressed in the glioma cells, a good correlation was observed between the expression level and the cell migration ability, determined by wound-healing assay. Correspondingly, overexpression of MYH9 abrogated ITE's migration-inhibiting effects, indicating that ITE-AHR inhibited cell migration via inhibiting MYH9 expression. MYH9 is essential for cell migration in 3D confined space and not a discovered target of AHR; the fact that ITE affects MYH9 via AHR opens a new research and development avenue.

Indexed as

GliomaAnimalsAntineoplastic AgentsBrainCell Line, TumorCell MovementCytoskeletonFemaleHumansIndolesMiceMice, Inbred C57BLMyosin Heavy ChainsReceptors, Aryl HydrocarbonThiazoles2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl esterAntineoplastic AgentsIndolesMyh9 protein, mouseMyosin Heavy ChainsReceptors, Aryl HydrocarbonThiazoles

Identifiers

PMID33083460
PMCPMC7556083
OpenAlexW3090137022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.